Bertrand Tuan, MD
Hematology-Oncology · San Francisco, CANPI 1578632980
Payments from drug & device makers
Across 567 payments — averaging $211.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$75K
- Johnson & Johnson$15K
- Rigel Pharmaceuticals, Inc.$11K
- Verastem, Inc.$7K
- AstraZeneca$850
- E.r. Squibb & Sons, L.L.C.$615
- plus $10K from 54 others
What the payments were for
- Consulting fees$8,37518%
- Speaking & faculty fees$23,40051%
- Travel & lodging$1390%
- Food & beverage$13,23829%
- Education$3091%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$119,746 in reported general payments places this provider in the 75th percentile of 53 hematology-oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 80 | $1,189,654 |
| PomalystPomalidomide | 37 | $827,373 |
| ReblozylLuspatercept-Aamt | 53 | $808,303 |
| RevlimidLenalidomide | 41 | $735,918 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 58 | $605,710 |
| ImbruvicaIbrutinib | 37 | $588,433 |
| NplateRomiplostim | 71 | $471,880 |
| IclusigPonatinib Hcl | 25 | $412,534 |
| BrukinsaZanubrutinib | 39 | $378,050 |
| NubeqaDarolutamide | 38 | $321,271 |
| TagrissoOsimertinib Mesylate | 30 | $311,092 |
| PromactaEltrombopag Olamine | 17 | $294,695 |
| AranespDarbepoetin Alfa In Polysorbat | 137 | $282,139 |
| ZejulaNiraparib Tosylate | 15 | $251,973 |
| NinlaroIxazomib Citrate | 18 | $224,654 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Pomalyst, Reblozyl | $615 | $1,635,67690 claims |
| AstraZenecaCalquence, Tagrisso | $850 | $1,500,746110 claims |
| AmgenNplate, Aranesp, Xgeva, Neulasta | $74,505 | $929,875255 claims |
| Bristol Myers SquibbRevlimid | $458 | $735,91841 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Iclusig, Ninlaro | $385 | $637,18843 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $395 | $588,43337 claims |
| Beigene USA, Inc.Brukinsa | $94 | $378,05039 claims |
| BayerNubeqa | $54 | $321,27138 claims |
| NovartisPromacta | $446 | $294,69517 claims |
| GSKZejula | $338 | $251,97315 claims |
| PfizerZirabev, Eliquis | $595 | $197,487150 claims |
| Lilly USA, LLCErbitux | $309 | $174,22823 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 53 hematology-oncology providers in California.
Other hematology-oncology in San Francisco
- Ari BaronSan Francisco$3.1M
- Jeffrey WolfSan Francisco$407K
- Xiaolin ZhuSan Francisco$112
- Noah YoungerSan Francisco$0
- Travis ZackSan Francisco$0
- Evan WalkerSan Francisco$0
- Annabel FrankSan Francisco$0
- Sant ChawlaSanta Monica$10.8M
- James BerensonWest Hollywood$8.4M
- Lee RosenSanta Monica$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.